Boyan Litchev
Keine laufenden Positionen mehr
Karriereverlauf von Boyan Litchev
Ehemalige bekannte Positionen von Boyan Litchev
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AKCEA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | - | - |
Shoreline Biosciences, Inc.
Shoreline Biosciences, Inc. BiotechnologyHealth Technology Shoreline Biosciences, Inc. engages in biotechnology business activities. The company is headquartered in La Jolla, CA. | Corporate Officer/Principal | 01.01.2021 | - |
POSEIDA THERAPEUTICS, INC. | Corporate Officer/Principal | - | - |
INDAPTUS THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 31.01.2022 | - |
Ausbildung von Boyan Litchev
Medical University of Plovdiv | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Bulgarien | 2 |
Operativ
Corporate Officer/Principal | 3 |
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 6 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
INDAPTUS THERAPEUTICS, INC. | Health Technology |
POSEIDA THERAPEUTICS, INC. | Health Technology |
HALOZYME THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Shoreline Biosciences, Inc.
Shoreline Biosciences, Inc. BiotechnologyHealth Technology Shoreline Biosciences, Inc. engages in biotechnology business activities. The company is headquartered in La Jolla, CA. | Health Technology |
Akcea Therapeutics, Inc.
Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Boyan Litchev
- Erfahrung